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ABSTRACT In this review, the Paediatric Assembly of the European Respiratory Society (ERS) presents a
summary of the highlights and most relevant findings in the field of paediatric respiratory medicine
presented at the virtual ERS International Congress 2020. Early Career Members of the ERS and Chairs of
the different Groups comprising the Paediatric Assembly discuss a selection of the presented research.
These cover a wide range of research areas, including respiratory physiology and sleep, asthma and allergy,
cystic fibrosis, respiratory infection and immunology, neonatology and intensive care, epidemiology,
bronchology and lung and airway development. Specifically, we describe the long-term effect in lung
function of premature birth, mode of delivery and chronic respiratory conditions such as cystic fibrosis. In
paediatric asthma, we present risk factors, phenotypes and their progression with age, and the challenges
in diagnosis. We confirm the value of the lung clearance index to detect early lung changes in cystic
fibrosis. For bronchiectasis treatment, we highlight the importance of identifying treatable traits. The use
of biomarkers and genotypes to identify infants at risk of long-term respiratory morbidity is also
discussed. We present the long-term impact on respiratory health of early life and fetal exposures to
maternal obesity and intrauterine hypoxia, mechanical ventilation hyperoxia, aeroallergens, air pollution,
vitamin A deficient intake and bronchitis. Moreover, we report on the use of metabolomics and genetic
analysis to understand the effect of these exposures on lung growth and alveolar development. Finally, we
stress the need to establish multidisciplinary teams to treat complex airway pathologies.
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CONGRESS HIGHLIGHTS
PAEDIATRICS
The Paediatric Assembly (Assembly 7) reviewed the latest paediatric respiratory research presented by
leading experts and early career members at the European Respiratory Society (ERS) virtual International
Congress 2020. More than 290 abstracts were presented by Assembly 7 members in several oral and
e-poster sessions. Assembly 7 also organised nine sessions including scientific symposia, Hot Topics,
Expert View, Grand Round, “Lungs on fire”, State of the Art and challenging clinical cases sessions, and
the Scientific Year in Review. With significant input from our Early Career Members, we here review some
of the major paediatric highlights from the ERS 2020 virtual International Congress 2020. The specific
sessions were selected by the Chairs of each of the eight groups that compose the Paediatric Assembly and
include oral and poster sessions, Hot Topics sessions, symposia and a live procedure.
Paediatric respiratory physiology and sleep
Although neonatal care has evolved dramatically in the last 30 years, few data exist on respiratory function
of preterm neonates in adult life. This was the focus of several studies in the oral presentations session of
the paediatric respiratory physiology and sleep group. BÅRDSEN et al. [1] studied three population-based
cohorts (1982–1985, 1991–1992 and 1999–2000) of young adults born extremely preterm (gestational age
<28 weeks) and compared them with adults born term by performing spirometry at the age of 18 years.
Subjects born extremely preterm had significantly lower forced expiratory volume in 1 s (FEV1) z-scores at
the age of 18 years; however, significant improvement of the respiratory function of the subjects born
extremely preterm was noted over the three decades. MARSOL et al. [2] investigated lung function
trajectories of 109 children born preterm with body plethysmography, bronchodilator test and spirometry
at the ages of 4, 5 and 6 years and compared these with lung function of children born at term. Even
though lung function in subjects born prematurely was lower at birth, no differences were noted during
preschool years, suggesting a catch-up of lung function in this group of children born prematurely.
MAHMOUD et al. [3] investigated whether mode of delivery can influence respiratory outcomes during the
first year of life. In this study, 580 full-term infants born by caesarean section (140 babies) or vaginal
delivery (440 babies) performed multiple breath washout (MBW) measurements, tidal breathing
measurements and were monitored for respiratory rate and symptoms during the first year of life.
Children born by caesarean section did not have higher rates of respiratory symptoms in the first year of
life. There were no differences in MBW or overall lung function between the two groups either.
During this same oral session, FOUZAS et al. [4] presented their findings on the pattern of FEV1 variability
in healthy children and adolescents. In total, 92 children aged 6–18 years performed spirometry twice per
day for 3 months. They showed that as age increased, the detrended fluctuation analysis of lung function
(DFA) α exponent, an index of a person’s lung function variability, decreased, and sample entropy of
FEV1 was elevated. These findings point to an increased adaptability of the respiratory system especially
through adolescence. KENTGENS et al. [5] investigated whether volumetric capnography (VCap) can reflect
ventilation inhomogeneity. In their study, MBW and VCap measurements from 63 healthy children and
50 children with cystic fibrosis (mean age 9.9 years) were evaluated. They found that obtaining
capnographic indices (CII) derived by VCap is feasible, and CII showed a significant correlation with lung
clearance index (LCI) in children with cystic fibrosis (r2=0.42; p<0.001). Thus, VCap seems promising as
an indicator of ventilation inhomogeneity but further studies are needed to reveal its minimal
methodological requirements along with its true clinical value.
Affiliations: 1Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 2Division of
Cancer and Stem Cells, Biodiscovery Institute, School of Medicine, University of Nottingham, University Park,
Nottingham, UK. 3Dept of General Paediatrics, Neonatology and Paediatric Cardiology, University Childreńs
Hospital, Heinrich-Heine-University, Duesseldorf, Germany. 4Paediatric Dept, 424 General Military Hospital,
Thessaloniki, Greece. 5Dept of Paediatric Respiratory Medicine, Royal Brompton Hospital, London, UK.
6Respiratory Physiology Laboratory, Medical School, University of Cyprus, Nicosia, Cyprus. 7Dept of
Paediatrics, Division of Respiratory Medicine and Allergology, Erasmus MC, University Medical Centre,
Rotterdam, The Netherlands. 8Centre for Genomics and Child Health, Blizard Institute, Queen Mary University
of London, London, UK. 9Women and Children’s Health, School of Life course Sciences, Faculty of Life
Sciences and Medicine, King’s College London, London, UK. 10Dept of Paediatrics, Division of Neonatology,
Erasmus MC, University Medical Centre, Rotterdam, The Netherlands. 11Division of Respirology, University of
Ottawa Children’s Hospital of Eastern Ontario, Ottawa, Canada. 12Department of Respiratory Sciences,
University of Leicester, Leicester, UK. 13Division of Infection, Immunity and Respiratory Medicine, University of
Manchester, Manchester, UK. 14Dept of Paediatrics, University Hospitals Leuven, Leuven, Belgium. 15Dept of
Paediatric Surgery, Erasmus Medical Centre – Sophia Children’s Hospital, Rotterdam, The Netherlands.
16Dept of Cell Biology, Erasmus MC, Rotterdam, the Netherlands. 17Division of Paediatric Pulmonology,
University Children’s Hospital Zurich, University of Zurich, Zurich, Switzerland. 18Department of Paediatrics,
Division of Paediatric Respiratory Medicine and Allergology, Erasmus MC, University Medical Centre,
Rotterdam, The Netherlands.
Correspondence: Cristina Ardura-Garcia, Institute of Social and Preventive Medicine, University of Bern,
Mittelstrasse 43, 3012 Bern, Switzerland. E-mail: cristina.ardura@ispm.unibe.ch
https://doi.org/10.1183/23120541.00893-2020 2
PAEDIATRICS | C. ARDURA-GARCIA ET AL.
In the field of paediatric sleep medicine, obesity and obstructive sleep apnoea (OSA) have been shown to
be associated with multifaceted derangements in metabolic and cardiovascular function, including
endothelial dysfunction. MYLEMANS et al. [6], examined whether weight loss can have an effect on
endothelial function and OSA in children with obesity and presented their findings during the oral
presentation session. After overweight subjects lost weight, their endothelial function improved, with
smaller improvements seen in the OSA subgroup, suggesting both OSA and obesity independently
increase the risk for endothelial dysfunction in children.
In the poster session of the Paediatric Respiratory Physiology and Sleep Group, HATZIAGOROU et al. [7]
showed the course of deterioration of LCI in cystic fibrosis patients from childhood to adulthood. In the
field of congenital lung malformations MACLEOD et al. [8] presented evidence showing that early surgical
treatment did not seem to be a significant influencing factor for long-term respiratory function. Many
studies also focussed on sleep disordered breathing (SDB) in the poster session. Of note, ERALP et al. [9]
found that a single polygraphy can be used as an adequate measure for paediatric OSA. LELLI et al. [10]
noted that the prevalence of SDB in children with chronic kidney disease was 10-times higher than in the
general paediatric population while BEYDON et al. [11] calculated the cut-offs for Snoring Index (SI) linked
to OSA, and found SI cut-offs of 172 h−1 and 267 h−1 to be linked to non-severe and severe OSA,
respectively.
In summary, this year’s novel research in paediatric physiology and sleep explored the long-term lung
function in children born prematurely and children with cystic fibrosis. Influence of mode of delivery and
surgical treatment on lung function was also studied. Additionally, researchers highlighted the variability
and adaptability of the respiratory system throughout childhood. Research supported the use of alternative
diagnostic methods for OSA and also investigators showed that obesity and OSA can independently
increase the risk of adverse health effects.
Paediatric asthma and allergy
The main themes that emerged in the “Hot Topics in Paediatric Asthma” session, included challenges in
asthma diagnosis, asthma phenotypes and their progression with age, risk factors for developing asthma
and asthma prevalence in primary care.
Starting with risk factors for asthma, SØRENSEN et al. [12] identified cases of severe bronchiolitis during
infancy and age-matched controls to examine the link with asthma at the age of 19 years. Current asthma
was more prevalent in the post-bronchiolitis group (24% versus 12%; p=0.005) and z-scores for FEV1,
forced expiratory flow at 25–75% of forced vital capacity (FVC) (FEF25–75%) and FEV1/FVC ratio were
significantly lower (p=0.003, 0.001 and 0.002, respectively). There was no difference in atopy between the
two groups (positive skin prick test (SPT) or specific immunoglobulin (Ig)E >0.35 kU·L−1). Lung function
in early childhood was not measured; therefore, we do not know whether genetically determined small
airways have contributed to these findings.
Moving on to asthma phenotyping, HOSE et al. [13] used patient questionnaires over 2 years to define
asthma phenotypes in children as part of the All Age Asthma Cohort (ALLIANCE) cohort in Germany.
Latent class analysis identified six latent classes (LC) as the best fit model. LC1 was characterised by
persistent symptoms but low atopy, LC2 by atopy and poor control and LC3 by atopy and good control.
LC4 had poor control but strong environmental trigger exposures including maternal smoking in
pregnancy. LC5 tended to be pre-school children in whom severe symptoms remitted after the first
hospitalisation and LC6 consisted of well-controlled, non-atopic children. When comparing classes with
LC6 (good control, non-atopic), over time, LC4 showed improvement in lung function (p=0.018 baseline
to follow up) but LC1 and LC5 showed a decline, and LC2 and LC3 showed raised eosinophils at baseline.
LC1 was also associated with the 17q21 risk allele (OR 2.43, 95% CI 1.07–5.53). This classification of
asthma phenotypes requires external validation and its subsequent utility to inform patient management
remains to be determined.
The role of eosinophils in phenotyping paediatric asthma was evaluated further by OMONY et al. [14], also
using data from the ALLIANCE cohort. Children with wheeze, and children and adults with asthma were
stratified into “atopy only”, “raised eosinophil only”, “T2 high” and “T2 low” categories. Only 6% of
children aged over 6 years showed raised eosinophils in isolation. Analysis of subcategories of age
demonstrated a decline in “eosinophil only” and “T2 low” asthma from birth to adulthood before
increasing again from the age of 30 years onwards. “Atopy only” asthma increased from birth until
adulthood. Children aged over 6 years with the “eosinophil only” phenotype had more exacerbations
within the preceding 12 months.
Continuing with asthma diagnosis, DE JONG et al. [15] used data from the Swiss Paediatric Airway Cohort
(SPAC) to examine the accuracy of asthma diagnosis in children, using clinical assessment and tests
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recommended by the Global Initiative for Asthma (GINA) and National Institute for Health and Care
Excellence (NICE). Of 514 participants, 69% were diagnosed with asthma. Symptoms of “any wheeze”,
“wheeze triggered by colds” and “wheeze triggered by exercise” produced the highest combined sensitivity
and specificity (Youden’s Index). Nocturnal cough was a poor discriminator. Total specific airway
resistance had the highest area under the receiver operator curve (AUC) (0.74) of any individual test,
although bronchodilator reversibility was highest (0.75) when used in children with a FEV1/FVC ratio
<0.8. Following the GINA algorithm, one-third of children would have required repeat testing to make a
diagnosis. Over 80% of children would have required 2 weeks of peak-flow monitoring to make an
accurate diagnosis using the NICE algorithm. The study confirms the difficulty in establishing the
diagnosis in all children based on objective tests.
Finally, CAVE et al. [16] presented data on the prevalence, clinical characteristics and aspects of
management of paediatric asthma in primary care in Canada. Prevalence of asthma in children aged
1–17 years was 18%, with the highest prevalence (20%) between 12 and 18 years of age. Median onset of
asthma was 7 years, with males outnumbering females at all ages up to 15 years. 13% of those diagnosed
required salbutamol treatment only, 66% had received inhaled corticosteroids (ICS) at some point, and 7%
had received a combination ICS/LABA inhaler. Only 1% had ever received oral steroids, and only 4% had
visited their doctor for asthma symptoms in the past 12 months, suggesting only a small proportion of
children in primary care in Canada have severe disease.
In summary, this year’s “Hot Topics in Paediatric Asthma” session explored the challenges of asthma
diagnosis and attempted to define some important asthma phenotypes. This raised discussion around the
utility of using the term “asthma” to represent a heterogeneous disease that may be more readily
characterised and managed as a series of “treatable traits”. Further work is required to characterise asthma
phenotypes and, in turn, improve diagnosis and personalised management for children.
Paediatric cystic fibrosis: New frontiers in CF imaging and lung physiology
This session focussed on techniques detecting and monitoring early lung changes in cystic fibrosis. The
presented studies described imaging and lung physiology results performed in children with cystic fibrosis.
BAYFIELD et al. [17] studied ultra-low-dose computed tomography in children with cystic fibrosis (aged
6–17 years). In this observational study, LCI and computed tomography were more sensitive at identifying
early lung disease than spirometry and oscillometry. Despite differences in quantitative metrics, both
conventional and ultra-low-dose computed tomography correlated with LCI and other MBW outcomes
and showed similar sensitivity to early lung changes. Importantly, the 78% radiation reduction with
ultra-low-dose computed tomography makes repeated scans a more feasible option. FRAUCHIGER et al. [18]
confirmed that LCI obtained by MBW was more sensitive than FEV1 to detect early lung disease in preschool
children. Instead of computed tomography, this group used functional matrix-pencil magnetic resonance
imaging (MP-MRI). This radiation-free method allows assessment of structural changes and visualisation and
quantification of ventilation impairment and perfusion defects. This was shown to correlate with LCI but not
FEV1, demonstrating a role in early lung disease detection in pre-schoolers with cystic fibrosis.
In a second paper from the group, FRAUCHIGER et al. [19] also presented data from an observational study
of LCI in 78 Swiss children with cystic fibrosis over a 7-year period. Average LCI remained stable during
childhood but increased during adolescence. Risk factors associated with faster LCI increase included
Pseudomonas spp. and Aspergillus fumigatus colonisation and cystic fibrosis-related diabetes. LCI also seemed
to deteriorate faster in female adolescents, even in absence of specific risk factors. STANOJEVIC et al. [20]
studied a similar longitudinal dataset although with some differences from the Swiss study. This study
followed LCI from 64 cystic fibrosis children and 50 controls from preschool into school age (to age
10 years). LCI was higher in children with cystic fibrosis, and elevated preschool LCI and greater number
of cystic fibrosis exacerbations were both predictors of higher school age LCI. However, unlike the Swiss
data, average LCI seemed to remain stable during these early school-age years. This may relate to subjects
being younger but may also reflect the evolving nature of cystic fibrosis therapies and increased treatment
intensity with cystic fibrosis transmembrane conductance regulator (CFTR) modulators and hypertonic
saline. PERREM et al. [21] studied the same cohort evaluating LCI as a clinical outcome in acute respiratory
events. LCI was increased and FEV1 was reduced by 10% at acute respiratory events, with an improvement
when pulmonary exacerbations were treated. Recovery, however, was incomplete and had not returned to
baseline by the next visit nor the next stable visit, suggesting that even milder untreated clinical events
contribute to disease progression. Furthermore, LCI was also confirmed to be more responsive than FEV1
to untreated increased cough events and acute respiratory events.
SPANO et al. [22] addressed some practical challenges of measuring LCI in clinical practice in a third
longitudinal LCI study in children with cystic fibrosis. This study showed an inverse correlation between
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LCI2.5 (LCI at 2.5% N2) and FEV1 %. For every unit increase in LCI there was a change of −2% FEV1%,
and for each unit increase in baseline LCI2.5, an average −2.5% change in FEV1% per year. This study
concluded that MBW is feasible in clinical settings but only if enough time for testing is provided.
PENNATI et al. [23] used multivolume MRI (1H-MRI) [24] as a method to assess regional intensity
differences between expiratory–inspiratory scans. Following on from an earlier study [25], changes in maps
of expiratory–inspiratory signal correlated with changes in FEV1 and FEF25–75%, indicating that
multivolume MRI could be used for longitudinal evaluation of regional alterations in cystic fibrosis lung
disease. This technique is radiation-free and can be carried out without inhaled or injected contrast.
Finally, WILLERS et al. [26] presented data demonstrating the feasibility of lung MRI in preschool children.
Unsedated lung MRI was feasible in pre-schoolers but depended on age and patient anxiety.
In discussion, the value of LCI in detecting early changes was recognised and reasserted, and the practical
challenges discussed. Mostly time constraints, but also lack of capacity, testing space or trained staff, lack
of real-time quality-controlled results, patient adherence and boredom prevent the incorporation of this
test into more routine cystic fibrosis care systems.
Paediatric respiratory infection and immunology: the future of bronchiectasis
management
Bronchiectasis is the characteristic end result of a complex interaction between inflammatory, infectious,
demographic and genetic factors on top of a heterogeneous spectrum of underlying aetiology [27]. The
session titled “The future of bronchiectasis management” provided an overview of the bronchiectasis
pathophysiology as well as recent developments in bronchiectasis management focussing on results of
recent randomised–controlled trials (RCTs). Although primarily adult oriented, the topic of this
symposium is also important in the context of paediatric non-cystic fibrosis bronchiectasis.
Recent evidence has emerged on the key role of mucus accumulation and its biophysical properties on
pathogenesis and severity of bronchiectasis. In more detail, RAMSEY et al. [28] have demonstrated that,
compared with healthy controls, bronchiectasis mucus was characterised by increased mucin
concentration (primarily MUC5AC and MUC5B), higher mucus solids and higher osmotic pressure.
Within bronchiectasis patients, mucus hyperconcentration was related to the extent of bronchiectasis and
lower lung function while the MUC5AC/MUCC5B ratio was predictive of disease severity [28]. These
results support the hypothesis of dehydrated mucus leading to inhibition of mucociliary clearance,
inflammation and recurrent respiratory infections [29]. Translated into clinical practice, identification of
patients with hyperconcentrated mucus, easily performed through measurement of dry-to-wet weight
ratio of mucus solids, followed by therapies reducing mucus concentration, such as hypertonic saline,
could provide significant benefits. Other than hypertonic saline, airway clearance techniques and
mannitol have already shown to improve lung function and health-related quality of life (HR-QoL) in
bronchiectasis [30–32].
The importance of the multimodality approach that should characterise bronchiectasis management, was
also highlighted during the session. Rather than a linear pathophysiological pathway that could be
disturbed with single treatment, bronchiectasis development is better described through a “vicious vortex”
model which includes epithelial and mucus dysfunction, abnormal inflammatory response, development of
structural disease and chronic recurrent infections. Based on this “vicious vortex” single treatments can
only influence one component of the vortex while other components remain unaffected [33]. As a result,
bronchiectasis treatment should address all aspects of the pathophysiology and include diagnosis of the
underlying aetiology, assessment of disease severity, airway clearance, antibiotic and anti-inflammatory
therapy [34].
Of particular interest, were the recent advances in management of chronic airway infection in
bronchiectasis. Regardless of the underlying aetiology, it has been shown that chronic infection, especially
with Pseudomonas aeruginosa, is associated with lower HR-QoL as well as increased hospitalisation rate
and mortality [35]. A recent individual patient data meta-analysis explored the effect of macrolides on
disease severity and found that macrolide treatment did not improve FEV1 but resulted in reduced
exacerbation frequency (adjusted incidence rate ratio 0.49, 95% CI 0.36–0.66; p<0.001) and improved
HR-QoL. Furthermore, subgroup analysis demonstrated that patients benefiting the most from macrolides
were older patients (>70 years), patients with high C-reactive protein and those colonised with
P. aeruginosa [36]. The finding that P. aeruginosa-colonised patients respond well to macrolides contradicts
the most recent ERS guidelines for long term antibiotic treatment for bronchiectasis which recommend
macrolides for non-P. aeruginosa-colonised patients and inhaled antibiotics for P. aeruginosa-colonised
patients [37]. Regarding inhaled antibiotics, a recent meta-analysis of 16 RCTs by LASKA et al. [38] also
reported a reduction in pulmonary exacerbation (RR 0.81, 95% CI 0.67–0.97; p=0.020) and severe
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exacerbation rate (RR 0.43, 95% CI 0.24–0.78; p=0·005) although the results were characterised by
significant heterogeneity and no effect was seen on quality of life. This observed heterogeneity indicates
the importance of correctly selecting the patients that are most likely to respond to inhaled antibiotics. Not
surprisingly, bronchiectasis patients with high bacterial load did appear to better respond to inhaled
antibiotics as opposed to patient groups with lower bacterial load [39, 40]. In P. aeruginosa-colonised
patients especially, inhaled antibiotics decreased pulmonary exacerbations [39]. In view of this evidence,
LASKA and CHALMERS [41] suggest a revised exacerbation prevention algorithm that applies in case of
persistent exacerbations after macrolide treatment and recommends inhaled antibiotics for patients with
high bacterial load, hypertonic saline or other mucoactive agents for patients with mucus plugging and
inhaled corticosteroids for patients with eosinophilic inflammation. Lastly, directly reducing inflammation
in bronchiectasis could also provide clinical benefits as brensocatib, an inhibitor of neutrophil serine
proteases activation, prolonged the time to the first exacerbation and decreased exacerbation frequency in a
randomised, double-blind trial in adults [42]. In regard to paediatric non-cystic fibrosis-related
bronchiectasis, targeting airway inflammation has also shown to be beneficial, especially through the
immunomodulatory properties of macrolides. Inhaled anti-inflammatories such as ICS, however, have not
been proven beneficial [43, 44].
In conclusion, identifying treatable traits of bronchiectasis based on the underlying aetiology, assessing
bacterial load and determining inflammatory molecular endotypes are key components for future precision
medicine in bronchiectasis.
Neonatology and paediatric intensive care: ventilation and chronic conditions
Chronic morbidity related to neonatal and paediatric pulmonary disease can often pose diagnostic and
therapeutic challenges. Novel research into identification of at-risk infants and children may lead to better
understanding of disease pathophysiology. Development of biomarkers and genotypes may enable
prediction of complications and advancement of appropriate management strategies.
Bronchopulmonary dysplasia (BPD) is a frequent and important respiratory outcome of premature birth
[45] with recent work focussing on predictive models and genetic markers. HIGANO et al. [46] developed a
tracheostomy prediction model in neonatal BPD from magnetic resonance imaging quantitative
biomarkers. The model correctly classified 95% of the validation cohort and provides an objective tool for
clinical decision making. Pulmonary hypertension is associated with severe BPD development [47].
HÄFNER et al. [48] showed that pulmonary arterial flow measurements taken from lung imaging are
decreased in infants with BPD and correlate with days of supplemental oxygen and mechanical ventilation.
This model may aid in early risk stratification of preterm infants with BPD and detect severity of lung
remodelling. PAVLINOVA et al. [49] related magnese superoxide dismutase (MnSOD) polymorphisms with
longer-term outcomes and reported that children with BPD and the MnSOD Ala16Val genotype had a 2.4
times increased risk of adverse respiratory outcomes compared to infants with respiratory distress
syndrome without BPD.
Longer term functional respiratory outcomes are important factors to consider in prematurely born
infants [50]. HARRIS et al. [51] assessed the lung function at 16–19 years of age in prematurely born infants
according to delivery mode at birth. Small airway function, as measured by mean FEF75, was greater in
those vaginally born (p=0.009) suggesting the onset of labour was important in priming the early immune
system. Preterm birth can also predispose infants to conditions such as patent ductus arteriosus. This may
require intervention in the neonatal period, yet surgical treatment can lead to vocal cord paralysis [52].
ENGAN et al. [53] compared lung function in affected young adults at follow up compared with a control
cohort and found peak oxygen consumption to be similar between the two groups (80% versus 79%), yet
both groups of extremely preterm infants assessed had reduced lung function and aerobic capacity
irrespective of vocal cord palsy.
Impairment of oxygenation in hepatopulmonary syndrome results from intrapulmonary shunting [54].
RUSSELL-JONES et al. [55] performed non-invasive measurements of ventilation-perfusion (V′/Q′) indices
and found a reversal of right-to-left intrapulmonary shunting post-liver transplant (p=0.009), yet there
remained a persistence of V′/Q′ abnormalities. Changes in pulmonary dead space may reflect V′/Q′ mismatch
[56]. WILLIAMS et al. [57] found the alveolar dead space to be increased in ventilated infants with evolving
BPD (p=0.001), suggesting underlying pulmonary abnormalities and disease induced changes which may
require ventilatory strategies with greater levels of targeted tidal volumes to allow for optimal gas exchange.
In conclusion, novel research was presented which can enable the identification of children and newborn
infants at risk of longer-term respiratory morbidity, with focus on genetic and predictive biomarkers,
suggesting this is a promising area for future development of pulmonary disease prevention or
interventions.
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Paediatric respiratory epidemiology
Early life is a very important developmental period that may affect respiratory health throughout the life
course. The results of several studies with a focus on early life exposures in relation to respiratory health
were presented in this session.
LUNDHOLM et al. [58] used data of two large cohorts from the Swedish Medical Birth register to study the
association of the airborne pollen concentration in pregnancy and infancy with current asthma in
childhood. They observed that exposure to high pollen levels in infancy was related to a higher risk of
asthma, whereas exposure to high pollen levels in pregnancy may protect against asthma.
Two abstracts focussed on the association of air pollution with lung function. ZHAO et al. [59] studied the
association of air pollution during infancy with lung function in children of two regions in Germany aged
6 years to adolescence, and found that a higher exposure to air pollutants particles with a 50% cut-off
aerodynamic diameter of 2.5 μm (PM2.5), 10 μm (PM10) and NO2 in the first year of life was associated
with a −0.004 to −0.027 z-score decline in FEV1 and FVC until adolescence. This association was stronger
in children who were breastfed for less than 12 weeks. Similarly, LUNDBERG et al. [60] found in
6-month-old infants, that higher time-weighted average air pollution levels including PM2.5, PM10 and
NO2 from birth onwards were related to a −8.39 to −10.40 mL lower FEV0.5 and FVC, which are related
to both obstructive and restrictive lung diseases later in life.
Two abstracts presented results on the relation of maternal diet in pregnancy with child’s respiratory
outcomes. Using individual participant data from seven European birth cohorts, MENSINK-BOUT et al. [61]
studied the overall maternal diet in pregnancy and observed that a more inflammatory diet in pregnancy
was related to a lower FVC in childhood, and that a very low dietary quality in pregnancy was related to
an up to 20% higher risk of pre-school wheezing, a low FEV1/FVC ratio and borderline with a higher risk
of school-age asthma. The study of PASHIRI et al. [62] focussed on the intake of preformed vitamin A in
mid-childhood in relation to lung function in adolescence, and they concluded that when comparing the
top versus the bottom quartile, a higher mid-childhood intake of preformed vitamin A, but not its
provitamin β-carotene, was associated with an up to 0.18 higher FEV1 and FEF25–75% z-score in
adolescence.
Regarding antenatal growth, TURNER et al. [63] linked antenatal and birth size to the onset of asthma up to
young adulthood, and mainly found that a low first trimester size as measured by crown rump length was
related to earlier time of asthma admission later in life but not with asthma per se. Also, those with a low
birth weight were younger when they obtained asthma medication for the first time.
The relationship of the frequency and duration of bronchitis in childhood with adverse respiratory
outcomes in middle-age was studied by PERRET et al. [64], and they observed that an increase in the
severity of bronchitis in childhood was associated with an increased risk of ever asthma or pneumonia, but
not consistently with the risk of chronic bronchitis or impaired lung function in adulthood.
In conclusion, in this session on paediatric respiratory epidemiology, it was highlighted that early life
exposure to a high pollen concentration, air pollution, a suboptimal dietary or vitamin A intake, growth
restriction and bronchitis might affect respiratory health throughout the life-course.
Paediatric bronchology
We here summarise a session on paediatric procedures and several oral and poster presentations that
covered many challenges and advances in paediatric bronchology. Treating complex airway pathologies
within a multidisciplinary team is a new rapidly emerging approach that was reflected in many of the
contributions alongside other interesting topics.
MCCARRICK et al. [65] showed the importance of multidisciplinary cooperation with paediatric ear, nose
and throat (ENT) doctors in a study in which they examined 164 clinical visits of 53 children with a
tracheal cannula. A flexible endoscopy was performed during 157 rounds, which showed tracheal
granulomas in eight, granulomas on the stoma in 12, and both tracheal and granulomas on the stoma in
two children. New recommendations regarding secretion management, tube change, fixation and skin care
were made in 97 rounds. The data showed a clear improvement in patient care with a significantly lower
number of procedures under general anaesthesia.
MUSSEL et al. [66] reported on the multidisciplinary collaboration with paediatric pneumologists, ENT and
gastroenterologists in children with relevant pathologies affecting all three disciplines. The author analysed
whether a combination of microlaryngoscopy, flexible bronchoscopy and oesophagogastroduodenoscopy
(OGD) is beneficial. For this, they studied the medical records of 79 children over the last 3 years. The
most common indication for an endoscopy was chronic cough. In 37 out of 79 children, an abnormality
was found in more than one endoscopy. In six out of 20 children who received all three procedures, a
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pathology was found in all three endoscopies. The data show that different endoscopies can be performed
in one setting and that the interdisciplinary exchange is thus greatly improved.
AMIGO et al. [67] tackled the complex diagnosis of primary ciliary dyskinesia (PCD) by including human
genetics. They designed a gene panel of 44 PCD-related genes with a sensitivity of 81% and a specificity of
100% for PCD diagnosis in 79 participants. They found 52 different gene variants, 36 not previously
described in the literature. The authors showed that a specific gene panel for the genetic diagnostic of
PCD is efficient and allows a better understanding of the cause of the disease, laying the basis for future
therapeutic approaches.
Three abstracts on the value of lung ultrasound (LUS) were presented, underlining the close and intensive
cooperation with radiology. BLOISE et al. [68] investigated the value of LUS in the diagnosis of community
acquired pneumonia. They showed a very good concordance in the diagnosis of right-sided consolidations.
The sensitivity in diagnosis was 97%, specificity 96%, sensitivity in follow-up 100%, specificity 94%.
DELESTRAIN et al. [69] performed LUS in five children with interstitial lung disease and compared the
images to the latest computed tomography scans. In this small cohort, the authors demonstrated a good
correlation between LUS and computed tomography images. Finally, LA REGINA et al. [70] examined the
use of LUS in bronchiolitis. They found a good correlation of the LUS score with the clinical score and
with radiography. They also reported a good correlation between the findings in children with
bronchiolitis and a control group.
A special highlight of the paediatric assembly was the live bronchoscopy performed by Dirk Schramm and
his team. They demonstrated the importance of multidisciplinary cooperation with anaesthesiologists
during interventional procedures. The patient presented suffered from juvenile-onset recurrent
papillomatosis, a rare disease in children younger than 12 years caused by human papilloma virus (HPV).
The mother was HPV-positive during birth and the patient has suffered from hoarseness since then. HPV
type 35, 45 and 87 were detected during the first bronchoscopy with bronchoalveolar lavage (BAL) at the
age of 3. A course of three vaccinations with Gardasil (recombinant human papillomavirus vaccine (types
6, 11, 16, 18)) were initiated and after the second immunisation, the virus was no longer detectable in the
BAL. After completion of all three vaccination cycles, a significant reduction of mucosal lesions could be
seen during the live bronchoscopy, though the hoarseness remained. HPV immunisation aims at
increasing the immune response and curing the disease.
To conclude, multidisciplinary cooperation is an important objective of providing exceptional patient care.
In paediatric bronchology, the involvement of other disciplines such as radiology or ENT has become an
integral part of clinical daily life.
Lung and airway developmental biology
This oral session covered various studies looking at effects on lung growth and alveolar development.
SELLE et al. [71] hypothesised that maternal obesity results in structural and functional changes in the
lungs via alteration of adipocytokines and specifically interleukin (IL)-6. Their murine model
demonstrated that maternal obesity activates IL-6 signalling in the lung of the offspring, with increased
senescence, resulting in reduced alveolar type 2 (ATII) cells and decreased alveolarisation in the offspring
lung. MOHR et al. [72] then continued the IL-6 story specifically looking at the impact on alveolar
formation in BPD. They demonstrated that an IL-6 deficiency protects against altered alveolar formation
after mechanical ventilation in BPD. This results in an upregulation of alveolar progenitor cells through a
downregulation in Krüppel-like factor 4 (Klf4) and it is this in ATII that promotes alveolarisation [72].
The story was completed by HIRANI et al. [73] with their study of the role of Klf4 in myofibroblast
transition and matrix remodelling after hyperoxia in BPD. They showed that downregulation in Klf4 may
result from hyperoxia associated with mechanical ventilation and showed that a reduction of Klf4
promotes myofibroblast trans-differentiation and, conversely, if there is overexpression of Klf4 there is a
complete block of myofibroblast trans-differentiation. Overall, they demonstrated that an overexpression of
Klf4 potentially results in a pro-fibrotic phenotype with induced lung growth and matrix remodelling [73].
Moving away from hyperoxia and mechanical ventilation, WANG et al. [74] presented their study on
intrauterine growth retardation (IUGR) and potential later life impacts, hypothesising that hypoxia
contributes to both IUGR and deficiency in development of airway smooth muscle. Their murine model
showed that reduced fetal size due to hypoxia positively correlated with airway smooth muscle thickness,
and a potential predisposition to asthma.
MIZIKOVA et al. [75] demonstrated a novel single-cell RNA analysis of the cell populations in normal and
impaired late lung development. This single-cell map of the developing lung in BPD used scRNA-Seq
MULTI-seq multiplex labelling of more than 66000 cells across three timepoints in 36 mice in either 21%
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or 85% oxygen. They found that, within the endothelium, hyperoxia gradually depletes Car4− cells and
increases Car4+ cells. This induces inflammatory and anti-angiogenic expression in capillary endothelial
cells, giving potential markers of changes induced by hyperoxia in the endothelium. Additionally, they
found a depleted alveolar macrophage population and increased circulating neutrophils after hyperoxia in
the second week of life [75].
WHEELOCK et al. [76] presented data from the LUNAPRE (lung obstruction in early adulthood or
prematurely born) cohort. They reported insights from the metabolomics of the cohort and current
clinical status. The BPD group had reduced FEV1/FVC ratio at 18–22 years, and a corresponding altered
and unique urinary eicosanoid profile with downregulation of thromboxane and prostaglandin D2. There
were also differences in profile between males and females with BPD.
BATOZHARGALOVA et al. [77] performed a case–control study looking for potential genes predisposing to
asthma in Buryat adolescents, an indigenous group from Mongolia. They identified three SNPs associated
with asthma; GSDMB (rs7216389), NOS1 (AAT)n and NOS3 (VNTR). Additionally, sex differences were
seen alongside a confirmation of the asthma association with SNPs in the 17q21 region GSDMB
(rs7216389) seen in other ethnic groups [78]. Further work explored gene–gene interactions in the cohort
with the GSDMB (rs7216389) SNP playing a key role.
Finally, DIACONU et al. [79] presented outcomes of a UK cohort of children treated with nusinersen for
spinal muscular atrophy. 12 patients had completed loading doses of nusinersen since 2017 and while
there were variable impacts on individual respiratory status, there was a 69% reduction in the number of
admissions to intensive care for respiratory exacerbations.
In conclusion, it is clear from the initial presentations that early life (and fetal exposures) have subsequent
impacts on the predisposition to asthma and BPD, and these mechanistic studies in conjunction with gene
analysis, give us a greater insight into this. Evolving methods such as single-cell RNA analysis will open
new research possibilities, while drugs such as nusinersen may have significant impacts on clinical
management of complex neuromuscular diseases opening up further horizons.
Concluding remarks
The latest research presented during the ERS virtual International Congress 2020 paediatric sessions
revealed key advances and concepts that will further the paediatric lung field. The importance of the
identification of early life exposures that may affect long-term pulmonary health, the characterisation of
phenotypes and genotypes, and the identification of biomarkers and treatable traits of different respiratory
diseases was highlighted throughout the sessions. These are key elements to develop new preventive
strategies and personalised management that may improve life-long respiratory health.
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